Last reviewed · How we verify
Standard-of-care endocrine treatment
Standard-of-care endocrine treatment is a Selective estrogen receptor degrader Small molecule drug developed by West German Study Group. It is currently in Phase 3 development for Hormone receptor-positive breast cancer.
Blocks estrogen receptors to prevent cancer cell growth.
Blocks estrogen receptors to prevent cancer cell growth. Used for Hormone receptor-positive breast cancer.
At a glance
| Generic name | Standard-of-care endocrine treatment |
|---|---|
| Sponsor | West German Study Group |
| Drug class | Selective estrogen receptor degrader |
| Target | Estrogen receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This is achieved by binding to estrogen receptors on cancer cells, thereby inhibiting the growth and proliferation of these cells. This is particularly effective in hormone receptor-positive breast cancer.
Approved indications
- Hormone receptor-positive breast cancer
Common side effects
- Hot flashes
- Musculoskeletal pain
- Fatigue
Key clinical trials
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion (NA)
- Re-Engineered Discharge for Diabetes Care Transitions (NA)
- Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (PHASE3)
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (PHASE3)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard-of-care endocrine treatment CI brief — competitive landscape report
- Standard-of-care endocrine treatment updates RSS · CI watch RSS
- West German Study Group portfolio CI
Frequently asked questions about Standard-of-care endocrine treatment
What is Standard-of-care endocrine treatment?
How does Standard-of-care endocrine treatment work?
What is Standard-of-care endocrine treatment used for?
Who makes Standard-of-care endocrine treatment?
What drug class is Standard-of-care endocrine treatment in?
What development phase is Standard-of-care endocrine treatment in?
What are the side effects of Standard-of-care endocrine treatment?
What does Standard-of-care endocrine treatment target?
Related
- Drug class: All Selective estrogen receptor degrader drugs
- Target: All drugs targeting Estrogen receptor
- Manufacturer: West German Study Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive breast cancer
- Compare: Standard-of-care endocrine treatment vs similar drugs
- Pricing: Standard-of-care endocrine treatment cost, discount & access